AU2007246144B2 - Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK - Google Patents

Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK Download PDF

Info

Publication number
AU2007246144B2
AU2007246144B2 AU2007246144A AU2007246144A AU2007246144B2 AU 2007246144 B2 AU2007246144 B2 AU 2007246144B2 AU 2007246144 A AU2007246144 A AU 2007246144A AU 2007246144 A AU2007246144 A AU 2007246144A AU 2007246144 B2 AU2007246144 B2 AU 2007246144B2
Authority
AU
Australia
Prior art keywords
seq
antibody
sequence
alk
antibody according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007246144A
Other languages
English (en)
Other versions
AU2007246144A1 (en
Inventor
Adrian Auf Der Maur
Alcide Barberis
Peter Lichtlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delenex Therapeutics AG
Original Assignee
Delenex Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delenex Therapeutics AG filed Critical Delenex Therapeutics AG
Publication of AU2007246144A1 publication Critical patent/AU2007246144A1/en
Assigned to DELENEX THERAPEUTICS AG reassignment DELENEX THERAPEUTICS AG Request for Assignment Assignors: ESBATECH AG
Priority to AU2012244351A priority Critical patent/AU2012244351B2/en
Application granted granted Critical
Publication of AU2007246144B2 publication Critical patent/AU2007246144B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007246144A 2006-04-28 2007-04-27 Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK Ceased AU2007246144B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012244351A AU2012244351B2 (en) 2006-04-28 2012-11-02 Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79583106P 2006-04-28 2006-04-28
US60/795,831 2006-04-28
PCT/CH2007/000202 WO2007124610A1 (en) 2006-04-28 2007-04-27 Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012244351A Division AU2012244351B2 (en) 2006-04-28 2012-11-02 Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK

Publications (2)

Publication Number Publication Date
AU2007246144A1 AU2007246144A1 (en) 2007-11-08
AU2007246144B2 true AU2007246144B2 (en) 2012-12-06

Family

ID=38515389

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007246144A Ceased AU2007246144B2 (en) 2006-04-28 2007-04-27 Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK

Country Status (16)

Country Link
US (3) US7902340B2 (https=)
EP (2) EP2013236B1 (https=)
JP (2) JP5431920B2 (https=)
KR (1) KR101457228B1 (https=)
CN (1) CN101443361B (https=)
AU (1) AU2007246144B2 (https=)
BR (1) BRPI0710971A2 (https=)
CA (1) CA2650822C (https=)
DK (1) DK2013236T3 (https=)
ES (1) ES2547248T3 (https=)
IL (1) IL194752A0 (https=)
MX (1) MX2008013705A (https=)
NZ (1) NZ572248A (https=)
PL (1) PL2013236T3 (https=)
RU (1) RU2460540C2 (https=)
WO (1) WO2007124610A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0710971A2 (pt) * 2006-04-28 2011-05-31 Esbatech Ag anticorpos que se ligam ao domìnio extracelular do receptor tirosina cinase alk,seu uso, vetor de expressão,método para produção de um antcorpo, vacina e epìtodo de alk
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
US20110206691A1 (en) * 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
KR102050040B1 (ko) 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
PL2307458T3 (pl) * 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
HK1220465A1 (zh) 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
CN104861069B (zh) * 2014-02-21 2018-12-18 无锡傲锐东源生物科技有限公司 针对间变性淋巴瘤激酶的单克隆抗体1a4及其用途
WO2015184231A2 (en) * 2014-05-30 2015-12-03 Kolltan Pharmaceuticals, Inc. Regulators of anaplastic lymphoma kinase and uses thereof
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
CA2940470C (en) 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
MY196631A (en) 2015-10-13 2023-04-24 Eureka Therapeutics Inc Antibody Agents Specific for Human Cd19 and uses Thereof
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
WO2017147408A1 (en) * 2016-02-25 2017-08-31 The Regents Of The University Of California Methods for the treatment of hematologic cancer
JP7538601B2 (ja) 2017-04-26 2024-08-22 ユーリカ セラピューティックス， インコーポレイテッド キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
JP7654402B2 (ja) * 2018-02-09 2025-04-01 アクセルロン ファーマ インコーポレイテッド 異所性骨化を処置するための方法
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN113960313B (zh) * 2021-12-22 2022-04-12 上海思路迪医学检验所有限公司 一种外泌体alk融合蛋白磁免疫化学发光检测试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21505A (en) * 1858-09-14 Improvement in bullet-machines
US6696548B2 (en) * 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
WO1998002462A1 (en) 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Immunoglobulin superfamily domains and fragments with increased solubility
JPH1116250A (ja) * 1997-06-20 1999-01-22 Pioneer Electron Corp 情報再生システム
ATE273323T1 (de) * 1999-12-28 2004-08-15 Esbatech Ag INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN
CA2412650C (en) 2000-06-14 2011-08-02 Georgetown University Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
JP2006508638A (ja) * 2002-05-22 2006-03-16 エスバテック・アーゲー 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
US7888485B2 (en) 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
WO2006020684A2 (en) 2004-08-10 2006-02-23 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
BRPI0710971A2 (pt) * 2006-04-28 2011-05-31 Esbatech Ag anticorpos que se ligam ao domìnio extracelular do receptor tirosina cinase alk,seu uso, vetor de expressão,método para produção de um antcorpo, vacina e epìtodo de alk

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Stoica, G. E. et al. Journal of Biological Chemistry (2002) Vol. 277, No. 39, pages 35990-35998 *

Also Published As

Publication number Publication date
RU2008146922A (ru) 2010-06-10
NZ572248A (en) 2011-08-26
RU2460540C2 (ru) 2012-09-10
JP5431920B2 (ja) 2014-03-05
JP2013226144A (ja) 2013-11-07
JP5911821B2 (ja) 2016-04-27
CA2650822C (en) 2017-03-14
CN101443361B (zh) 2015-08-19
JP2009535021A (ja) 2009-10-01
US20110159008A1 (en) 2011-06-30
EP2013236A1 (en) 2009-01-14
BRPI0710971A2 (pt) 2011-05-31
US9512411B2 (en) 2016-12-06
HK1124619A1 (en) 2009-07-17
IL194752A0 (en) 2011-08-01
AU2007246144A1 (en) 2007-11-08
CN101443361A (zh) 2009-05-27
DK2013236T3 (en) 2015-09-21
US20080118512A1 (en) 2008-05-22
MX2008013705A (es) 2008-11-06
CA2650822A1 (en) 2007-11-08
EP2013236B1 (en) 2015-06-17
EP2604627A1 (en) 2013-06-19
KR101457228B1 (ko) 2014-11-04
KR20080113261A (ko) 2008-12-29
US7902340B2 (en) 2011-03-08
US8945563B2 (en) 2015-02-03
ES2547248T3 (es) 2015-10-02
PL2013236T3 (pl) 2015-12-31
US20150203829A1 (en) 2015-07-23
WO2007124610A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
AU2007246144B2 (en) Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK
KR102037016B1 (ko) 항 pd-l1 나노 항체 및 이의 응용
JP7336122B2 (ja) 抗ｖｅｇｆ単一ドメイン抗体およびその応用
US20230416379A1 (en) ALK7 Binding Proteins and Uses Thereof
TW201609812A (zh) 最佳化之跨物種特異性雙特異性單鏈抗體構築體
CN111825766B (zh) 抗il-4r单域抗体及其应用
CN115397857B (zh) 一种抗pd-l1和pd-l2抗体及其衍生物和用途
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
JP7617036B2 (ja) Ａｌｋ７結合タンパク質及びその使用
WO2008131575A2 (en) Anti-alk antibodies suitable for treating metastatic cancers or tumors
AU2012244351B2 (en) Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK
CN111108120A (zh) 抗人类血管内皮生长因子受体的抗体及其应用
US20240101663A1 (en) Method for inhibiting tumour cell growth based on ccdc112
KR102960935B1 (ko) 항 pd-l1 및 pd-l2 항체 및 이의 유도체 및 용도
HK1124619B (en) Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
HK40105152A (zh) 对muc18特异性的抗体
TWI922781B (zh) Ｄｌｌ３及ｃｄ３抗體構築體、其醫藥組合物、套組及用途
HK40060753B (zh) 对muc18特异性的抗体

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DELENEX THERAPEUTICS AG

Free format text: FORMER APPLICANT(S): ESBATECH AG

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired